ID
45550
Descrizione
Principal Investigator: Edwin Cook, MD, University of Illinois at Chicago (UIC), Chicago, IL, USA MeSH: Autistic Disorder,Developmental Disabilities https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000712 Autism spectrum disorder (ASD) is highly heritable with recent sibling recurrence risk estimates of 19% overall and 26% in males. The heritable phenotype of hyperserotonemia, or elevated levels of platelet serotonin (5HT), in ~35% of people with ASD is a well-established biomarker. The efficacy of drugs like risperidone and potent serotonin transporter inhibitors at treating behaviors related to Insistence on Sameness, along with evidence of the contribution of hyperserotonemia to autism susceptibility collectively support the hypothesis that dysfunction in the 5HT system is a significant etiological target for investigation of the genetic component to autism. ASD genetic architecture is complex; common variants of large effect do not contribute substantially to overall ASD risk, but there are clearly common variants with small effects and rare genetic/genomic variation of larger effect among ASD genetic risk factors. The NIH ARRA Autism Sequencing Consortium, including Dr. Sutcliffe and Dr. Cook among others, has initiated exome sequencing studies to identify more of the rare variants contributing to ASD. Data from our group and others reveal numerous rare *de novo* and inherited sequence mutations, and the number of *de novo* and other functional mutations that are found to affect molecules encoding 5HT signaling and its regulation further reinforces our hypothesis that regulation of serotonin levels is important in autism genetic susceptibility. Integrin receptor signaling pathways were prominently featured among identified de novo mutations, thus defining a set of interrelated gene networks that control 5HT signaling. We propose to extend our findings to date by conducting exome sequencing on ACE subjects, for whom we also have 5HT biochemical data, to identify rare variants (including CNVs) in 5HT-related gene networks. In total we propose to have exome sequencing completed on 523 samples. The purpose of the proposed research is two-fold: 1) we will conduct more extensive investigations to determine the support for the hypothesis that genetic variation at genes regulating platelet serotonin levels affect susceptibility to ASD and 2) we will combine the exome sequence data from these studies with sequence data for autism being accumulated in a variety of other research projects to further the goal of identifying and characterizing the genetic component to ASD.
collegamento
Keywords
versioni (1)
- 09/01/23 09/01/23 - Chiara Middel
Titolare del copyright
Edwin Cook, MD, University of Illinois at Chicago (UIC), Chicago, IL, USA
Caricato su
9 gennaio 2023
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
dbGaP phs000712 UIC ACE Exome Sequencing Analysis
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent data table contains subject IDs, consent information, subject aliases, and affection status.
- The pedigree table includes subject ID, family ID, father and mother ID, and subject gender to link subjects of the same family.
- This data table contains mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table includes subject gender, ancestry, ethnicity, race, paternal and maternal age at proband's birth, blood draw age, subject's relationship to proband, and final diagnosis. Physical observations include Tanner staging (n=6 variables) and CHARGE physical exam (n=9 variables). Laboratory measurements include serotonin (WB5HT) measurements (n=6 variables), karotype abnormalities, fragile-X test, duplication testing, and MRI. Psychological and Psychiatric Measurements include the following: cognitive measurments (n=11 variables), ADI-R (n=21 variables), VABS-II (n=6 variables), ADOS (n=12 variables), PPVT-4 (n=4 variables), EOWPVT (n=4 variables), CELF (n=3 variables), PLS-4 (n=4 variables), ABC-CV (n=6 variables), SCQ (n=3 variables), SRS (n=11 variables), RBS-R (n=9 variables), OCI-R (n=8 variables), CRI (n=4 variables), BAPQ (n=11 variables), PRL (n=9 variables), and SST (n=4 variables).
- This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, DNA extraction method, genotyping and sequencing center.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent data table contains subject IDs, consent information, subject aliases, and affection status.
- The pedigree table includes subject ID, family ID, father and mother ID, and subject gender to link subjects of the same family.
- This data table contains mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table includes subject gender, ancestry, ethnicity, race, paternal and maternal age at proband's birth, blood draw age, subject's relationship to proband, and final diagnosis. Physical observations include Tanner staging (n=6 variables) and CHARGE physical exam (n=9 variables). Laboratory measurements include serotonin (WB5HT) measurements (n=6 variables), karotype abnormalities, fragile-X test, duplication testing, and MRI. Psychological and Psychiatric Measurements include the following: cognitive measurments (n=11 variables), ADI-R (n=21 variables), VABS-II (n=6 variables), ADOS (n=12 variables), PPVT-4 (n=4 variables), EOWPVT (n=4 variables), CELF (n=3 variables), PLS-4 (n=4 variables), ABC-CV (n=6 variables), SCQ (n=3 variables), SRS (n=11 variables), RBS-R (n=9 variables), OCI-R (n=8 variables), CRI (n=4 variables), BAPQ (n=11 variables), PRL (n=9 variables), and SST (n=4 variables).
- This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, DNA extraction method, genotyping and sequencing center.
C0680251 (UMLS CUI [1,2])
C1707689 (UMLS CUI [1,2])
C0002045 (UMLS CUI [1,2])
C1510586 (UMLS CUI [1,3])
C0004352 (UMLS CUI [1,4])
C1441495 (UMLS CUI [2,1])
C0011900 (UMLS CUI [2,2])
C0004352 (UMLS CUI [2,3])
C1510586 (UMLS CUI [2,4])
C1298908 (UMLS CUI [1,2])
C0019247 (UMLS CUI [1,3])